Avenacy Introduces Tranexamic Acid Injection to the U.S. Market

The FDA approved therapeutic generic counterpart of Cyklokapron, Tranexamic Acid Injection, USP, has been introduced in the US by Avenacy, a specialty pharmaceutical business that specialises in providing vital injectable drugs.

For brief usage of 2 to 8 days, tranexamic acid injection, USP is recommended for haemophiliac individuals in order to lessen or avoid bleeding and decrease the need for substitute medication both during and after tooth extraction.

Jeff Yordon, co-founder and CEO of Avenacy Stated: “Since our company’s inception in October 2023, we have aimed to quickly deliver safe, effective, quality specialty injectables to hospitals and providers across the U.S., and the launch of Tranexamic Acid injection marks another important step in fulfilling this mission. The rest of 2024 is poised to be a transformative year for the business, as we remain focused on launching several additional products.”

Avenacy will start supplying its wholesale partners with Tranexamic Acid Injection. The organisation is bolstered by an international community of contract manufacturing and research collaborators that have successfully completed FDA inspections using cGMP criteria.